

Supporting Information

Thiols-promoted intermolecular cyclization to synthesize 1,2,4-oxadiazoles including *Tioxazafen* under transition metal-free conditions

Congcong Yan^a, Min Zhang^a, Jiaxin Li^a, Jinli Zhang^{a,b*}, Yangjie Wu^{a,b}

^a*Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450001, P. R. China*

^b*Henan Key Laboratory of Chemical Biology and Organic Chemistry; Key Laboratory of Applied Chemistry of Henan Universities, Zhengzhou University, Zhengzhou, 450052, P.R. China*

*Corresponding author, E-mail: jinli@zzu.edu.cn

Table of Contents


1. General Information.....	2
2. Experimental Procedure	2
2.1 Procedure for synthesis of amidoxime and its derivatives.....	2
2.2 Procedure for synthesis of 1,2,4-oxadiazole and its derivatives	2
3. Exploring the Mechanism	3
3.1 Exploring the Mechanism by high Resolution Mass Spectrometry Tracking Experiments	3
3.2 Exploring the Mechanism by pH detection	6
4. Characterization Data of Products	7
5. Copies of ¹ H, ¹³ C, ¹⁹ F NMR Spectra for the Products	21
6. References.....	83

1. General Information

¹H NMR, ¹³C NMR, ¹⁹F NMR were recorded in CDCl₃ at room temperature on the Bruker DPX-400 spectrometer (400 MHz, 101 MHz, 376 MHz). The chemical-shifts scale is based on internal TMS. Low-resolution mass spectra data were obtained by LC/MSD Trap XCT Melting points were measured using a WC-1 microscopic apparatus and are uncorrected. High-resolution mass spectra (HRMS) were recorded on Thermo Scientific Q Exactive. All reactions were monitored and post-processing by TLC with Qingdao GF₂₅₄ silica gel-coated plates. Aryl nitriles and benzyl mercaptans were purchased from commercial suppliers such as Aladdin or J&K Scientific and used without further purification unless otherwise noted. The amidoximes were synthesized according to the synthetic methods reported in the literature (See 2.1).


2. Experimental Procedure

2.1 Procedure for synthesis of amidoxime and its derivatives^[1]



In a round-bottom flask, under magnetic stirring, aryl nitrile (15 mmol) was dissolved in ethanol (25 mL), and to the solution hydroxylamine hydrochloride (2.085 g, 30 mmol) and aqueous NaOH (2 equiv., 10 mL) were added. The mixture was stirred at 80 °C for 2 to 3 h, and the reaction was monitored by TLC. Then, the solvent was removed by rotary evaporation and water was added to the crude mixture (20 mL). The mixture was extracted with ethyl acetate (3 x 10 mL) and the organic layer was dried over anhydrous Na₂SO₄ and filtered. The solvent was removed by rotary evaporation and the crude product was purified through flash column chromatography on silica gel using petroleum ether/ethyl acetate = (1/1), and dried under reduced pressure.


2.2 Procedure for synthesis of 1,2,4-oxadiazole and its derivatives



To a mixture of amidoxime (0.20 mmol), benzyl mercaptan (0.40 mmol), Cs_2CO_3 (130.3 mg, 2.0 equiv.), and CH_3CN (1 mL) were added in a 25 mL screw-cap Schlenk test tube. Then the mixture was stirred at 80°C for 5 h under air atmosphere. The progress of the reaction was monitored by TLC. After the reaction was completed, the reaction mixture was cooled to room temperature and then filtered with diatomite. The mixture was extracted with ethyl acetate (3×10 mL) and the combined organic phases were dried over anhydrous Na_2SO_4 and the solvent was evaporated under vacuum. The residue was purified by column chromatography to give the corresponding products (petroleum ether/dichloromethane = 3/1 - 5/1, 18%-95%).

3. Exploring the Mechanism

3.1 Exploring the Mechanism by high Resolution Mass Spectrometry Tracking Experiments



A mixture of **1a** (0.2 mmol, 27.2 mg) and **2a** (0.4 mmol, 48 μ L), Cs_2CO_3 (130.3 mg), and CH_3CN (1.0 mL) was heated under an air atmosphere in a Schlenk tube at 80°C . The reaction was monitored for 0.5 h, 1 h, 1.5 h, 2 h, 3 h, 4 h, and 5 h. After the reaction was finished, the reaction mixture was cooled to room temperature. The mixture was extracted with CH_2Cl_2 (3×10 mL), the combined organic phases were dried over anhydrous Na_2SO_4 and the solvent was evaporated under vacuum. The samples were detected by high resolution mass spectrometry. The test results are as follows.




Figure 1 The mass spectrum for **2 h** of the reaction solution of **1a** and **2a**




Figure 2 The mass spectrum for **1 h** of the reaction solution of **1a** and **2a**




Figure 3 The mass spectrum for **1 h** of the reaction solution of **1a** and **2a**




Figure 4 The mass spectrum for **1.5 h** of the reaction solution of **1a** and **2a**






Figure 5 The mass spectrum for **2 h** of the reaction solution of **1a** and **2a**

3.2 Exploring the Mechanism by pH detection

Mix benzyl thiol (**2a**, 0.4 mmol, 48 μ L), Cs₂CO₃ (130.3 mg), and CH₃CN (1.0 mL) under an air atmosphere in a Schlenk tube. The pH of the mixed solution was detected to be 9, which further proved the possibility of producing intermediate **A**.




4. Characterization Data of Products



3,5-diphenyl-1,2,4-oxadiazole (3aa)^[2]

White solid; 95% yield (42.2 mg); mp: 107.5-109.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.17 (m, 4H), 7.62-7.48 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 175.73, 168.99, 132.75, 131.21, 129.12, 128.87, 128.19, 127.55, 127.00, 124.34.




5-phenyl-3-(o-tolyl)-1,2,4-oxadiazole (3ba)^[3]

White solid; 70% yield (33.1 mg); mp: 110.3-111.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (m, 2H), 8.10-8.08 (m, 1H), 7.62-7.52 (m, 3H), 7.42-7.38 (m, 1H), 7.35-7.33 (m, 2H), 2.69 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.73, 169.60, 138.28, 132.69, 131.40, 130.60, 129.12, 128.19, 126.26, 126.10, 124.37, 22.15.




3-(2-methoxyphenyl)-5-phenyl-1,2,4-oxadiazole (3ca)^[4]

White solid; 76% yield (38.4 mg); mp: 113.2-113.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.21 (m, 2H), 8.13-8.11 (m, 1H), 7.61-7.47 (m, 4H), 7.13-7.06 (m, 2H), 3.99 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.56, 167.46, 158.18, 132.61, 132.33, 131.44, 129.06, 128.20, 124.39, 120.71, 55.02.




3-(2-chlorophenyl)-5-phenyl-1,2,4-oxadiazole (3da)^[5]

White solid; 86% yield (44.1 mg); mp: 86.7-87.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.21 (m, 2H), 8.03-8.01 (m, 1H), 7.63-7.59 (m, 1H), 7.57-7.53 (m, 3H), 7.47-7.39 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.28, 167.79, 133.55, 132.90, 131.79, 131.72, 130.95, 129.16, 128.24, 126.92, 126.29, 124.09.




3-(2-iodophenyl)-5-phenyl-1,2,4-oxadiazole (3ea)

White solid; 66% yield (44.1 mg); mp: 68.3-68.9 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.24-8.21 (m, 2H), 8.06-8.04 (m, 1H), 7.83-7.80 (m, 1H), 7.64-7.51 (m, 3H), 7.49-7.47 (m, 1H), 7.21-7.17 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.47, 169.79, 140.90, 132.94, 132.23, 131.80, 131.45, 129.19, 128.26, 128.18, 124.12, 95.33; HRMS (m/z) [M+H]⁺ calculated for C₁₄H₉IN₂O: 348.9832; found: 348.9832.




5-phenyl-3-(2-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3fa)

Colourless liquid; 76% yield (44.1mg); ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.20 (m, 2H), 7.88-7.85 (m, 2H), 7.71-7.60 (m, 3H), 7.57-7.53 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.68, 168.15, 132.99, 131.87 (d, J = 2.3 Hz), 130.74, 129.52 (q, J = 32.1 Hz) 129.19, 128.25, 126.92 (q, J = 5.3 Hz), 125.86 (d, J = 1.9 Hz), 123.98, 123.48 (q, J = 273.6 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -58.70; HRMS (m/z) [M+H]⁺ calculated for C₁₅H₉F₃N₂O: 291.0740; found: 291.0740.



5-phenyl-3-(m-tolyl)-1,2,4-oxadiazole (3ga)^[2]


White solid; 88% yield (41.5 mg); mp: 85.1-85.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.21 (m, 2H), 8.00-7.97 (m, 2H), 7.62-7.52 (m, 3H), 7.39 (t, J = 7.7 Hz, 1H), 7.32 (d, J = 7.7 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.65, 169.09, 138.66, 132.72, 131.99, 129.11, 128.79, 128.18, 128.09, 126.84, 124.68, 124.36, 21.40.



3-(3-chlorophenyl)-5-phenyl-1,2,4-oxadiazole (3ha)^[5]

White solid; 90% yield (46.1 mg); mp: 102.1-103.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.17 (m, 3H), 8.07-8.04 (m, 1H), 7.63-7.60 (m, 1H), 7.56-7.52 (m, 2H),

7.50-7.47 (m, 1H), 7.43 (t, $J = 7.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.98, 167.97, 134.96, 132.92, 131.23, 130.18, 129.16, 128.72, 128.20, 127.65, 125.58, 124.10.




3-(3-bromophenyl)-5-phenyl-1,2,4-oxadiazole (3ia)^[6]

White solid; 84% yield (50.3 mg); mp: 91.5-92.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.33 (t, $J = 1.6$ Hz, 1H), 8.21-8.19 (m, 2H), 8.09 (d, $J = 7.7$ Hz, 1H), 7.65-7.59 (m, 2H), 7.56-7.52 (m, 2H), 7.37 (t, $J = 7.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.98, 167.84, 134.16, 132.93, 130.53, 130.42, 129.16, 128.94, 128.20, 126.03, 124.09, 122.96.




3-phenyl-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3ja)^[7]

White solid; 78% yield (45.2 mg); mp: 90.6-91.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.45 (s, 1H), 8.35 (d, $J = 8.0$ Hz, 1H), 8.23-8.21 (m, 2H), 7.77 (d, $J = 7.7$ Hz, 1H), 7.65-7.60 (m, 2H), 7.57-7.53 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.17, 167.94, 132.99, 131.46 (q, $J = 33.1$ Hz), 130.62, 129.44, 129.18, 128.22, 127.89, 127.75 (q, $J = 5.5$ Hz), 124.52 (q, $J = 3.9$ Hz), 124.01, 123.81 (q, $J = 273.2$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -62.79.




5-phenyl-3-(p-tolyl)-1,2,4-oxadiazole (3ka)^[2]

White solid; 81% yield (38.2 mg); mp: 101.0-102.1 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.22-8.19 (m, 2H), 8.06 (d, $J = 8.1$ Hz, 2H), 7.61-7.51 (m, 3H), 7.30 (d, $J = 8.1$ Hz, 2H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.56, 168.99, 141.51, 132.68, 129.58, 129.09, 128.17, 127.47, 124.41, 124.17, 21.62.




3-(4-methoxyphenyl)-5-phenyl-1,2,4-oxadiazole (3la)^[3]

White solid; 74% yield (37.3 mg); mp: 101.4-102.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.19 (m, 2H), 8.11 (d, *J* = 8.7 Hz, 2H), 7.61-7.51 (m, 3H), 7.01 (d, *J* = 9.0 Hz, 2H), 3.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.44, 168.67, 161.94, 132.65, 129.14, 129.08, 128.15, 124.43, 119.45, 114.25, 55.40.




3-(4-(*tert*-butyl)phenyl)-5-phenyl-1,2,4-oxadiazole (3ma)^[8]

White solid; 90% yield (50 mg); mp: 135.5-136.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.21 (m, 2H), 8.11-8.09 (m, 2H), 7.61-7.52 (m, 5H), 1.37 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 175.56, 168.94, 154.61, 132.67, 129.09, 128.19, 127.34, 125.84, 124.44, 124.15, 35.10, 31.22.




3-(4-fluorophenyl)-5-phenyl-1,2,4-oxadiazole (3na)^[8]

White solid; 81% yield (39.1 mg); mp: 111.3-112.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.15 (m, 4H), 7.62-7.52 (m, 3H), 7.22-7.16 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.80, 168.15, 164.60 (d, *J* = 254.5 Hz), 132.82, 129.69 (d, *J* = 8.8 Hz), 129.13, 128.17, 124.21, 123.22 (d, *J* = 3.1 Hz), 116.04 (d, *J* = 22.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -108.52.




3-(4-iodophenyl)-5-phenyl-1,2,4-oxadiazole (3oa)

White solid; 91% yield (63.3 mg); mp: 126.4-126.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.19 (m, 2H), 7.91-7.84 (m, 4H), 7.63-7.59 (m, 1H), 7.57-7.53 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.93, 168.41, 138.12, 132.90, 129.16, 129.05, 128.20, 126.49, 124.14, 97.92; HRMS (m/z) [M+H]⁺ calculated for C₁₄H₉IN₂O: 348.9832; found: 348.9832.




3-(4-chlorophenyl)-5-phenyl-1,2,4-oxadiazole (3pa)^[8]

White solid; 86% yield (47.4 mg); mp: 101.1-101.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.19 (m, 2H), 8.11 (d, *J* = 8.7 Hz, 2H), 7.63-7.53 (m, 3H), 7.49-7.47 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.90, 168.17, 137.34, 132.88, 129.19, 129.15, 128.85, 128.19, 125.49, 124.15.




3-(4-bromophenyl)-5-phenyl-1,2,4-oxadiazole (3qa)^[8]

White solid; 79% yield (24 mg); mp: 110.8-112.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.22-8.20 (m, 2H), 8.06-8.04 (m, 2H), 7.66-7.64 (m, 2H), 7.62-7.60 (m, 1H), 7.58-7.54 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.94, 168.27, 132.90, 132.16, 129.16, 129.04, 128.20, 125.94, 125.76, 124.14.




5-phenyl-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3ra)^[9]

White solid; 90% yield (52.2 mg); mp: 125.2-126.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 8.1 Hz, 2H), 8.22-8.20 (m, 2H), 7.76 (d, *J* = 8.1 Hz, 2H), 7.64-7.60 (m, 1H), 7.55 (t, *J* = 7.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 176.18, 167.96, 133.01, 132.89 (d, *J* = 32.7 Hz), 130.39, 129.19, 128.21, 127.88, 125.84 (q, *J* = 8.1 Hz), 124.02, 123.82 (d, *J* = 272.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -62.94




3-(naphthalen-1-yl)-5-phenyl-1,2,4-oxadiazole (3sa)^[8]

White solid; 73% yield (48.4 mg); mp: 121.7-122.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.98 (d, *J* = 8.5 Hz, 1H), 8.36 (d, *J* = 7.3 Hz, 1H), 8.29-8.26 (m, 2H), 8.01 (d, *J* = 8.2 Hz, 1H), 7.93 (d, *J* = 8.2 Hz, 1H) 7.67-7.54 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 174.90, 169.43, 133.94, 132.82, 131.86, 130.74, 129.46, 129.18, 128.69, 128.29, 127.60, 126.35 (d, *J* = 8.2 Hz), 125.16, 124.31, 123.99.




3-cyclopropyl-5-phenyl-1,2,4-oxadiazole (3ta)^[10]

White solid; 51% yield (19.0 mg); mp: 35.8-36.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.09-8.07 (m, 2H), 7.59-7.54 (m, 1H), 7.52-7.48 (m, 2H), 2.18-2.12 (m, 1H), 1.15-1.06 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 175.14, 173.06, 132.51, 128.99, 128.03, 124.41, 7.76, 6.94.



5-phenyl-3-(pyridin-2-yl)-1,2,4-oxadiazole (3ua)^[5].

Yellow solid; 91% yield (40.7 mg); mp: 131.4-131.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.85-8.84 (m, 1H), 8.29-8.27 (m, 2H), 8.23-8.21 (m, 1H), 7.90-7.85 (m, 1H), 7.64-7.59 (m, 1H), 7.57-7.53 (m, 2H), 7.47-7.43 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.47, 168.78, 150.44, 146.46, 137.06, 132.95, 129.10, 128.33, 125.53, 123.99, 123.26.




3-(furan-2-yl)-5-phenyl-1,2,4-oxadiazole (3va)

White solid; 87% yield (36.9 mg); mp: 119.3-119.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.19 (m, 2H), 7.64 (d, *J* = 1.0 Hz, 1H), 7.63-7.59 (m, 1H), 7.54 (t, *J* = 7.9 Hz, 2H), 7.21 (d, *J* = 3.3 Hz, 1H), 6.59 (q, *J* = 1.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.74, 161.90, 145.20, 142.40, 132.98, 129.13, 128.26, 123.87, 113.78, 111.87; HRMS (m/z) [M+H]⁺ calculated for C₁₂H₈N₂O₂: 213.0659; found: 213.0660.




5-phenyl-3-(thiophen-2-yl)-1,2,4-oxadiazole (3wa)^[11]

White solid; 92% yield (42.0 mg); mp: 131.2-131.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.18 (m, 2H), 7.88-7.87 (m, 1H), 7.62-7.58 (m, 1H), 7.55-7.51 (m, 3H), 7.18-7.16 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.64, 165.05, 132.89, 129.64, 129.28, 129.12, 128.56, 128.24, 127.99, 124.03.




3-phenyl-5-(*o*-tolyl)-1,2,4-oxadiazole (3ab)^[2]

White solid; 44% yield (23.1 mg); mp: 55.2-55.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.15 (m, 3H), 7.52-7.45 (m, 4H), 7.38-7.35 (m, 2H), 2.79 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.36, 168.61, 139.17, 132.21, 131.92, 131.15, 130.22, 128.86, 127.54, 127.14, 126.29, 123.49, 21.99.




5-(2-chlorophenyl)-3-phenyl-1,2,4-oxadiazole (3ac)^[12]

Colourless liquid; 32% yield (25.7 mg); mp: 55.1-56.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.18 (m, 2H), 8.17-8.14 (m, 1H), 7.61-7.58 (m, 1H), 7.54-7.50 (m, 4H), 7.47-7.43 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.34, 168.72, 133.91, 133.14, 131.95, 131.47, 131.31, 128.91, 127.60, 127.11, 126.78, 123.70.




5-(2-bromophenyl)-3-phenyl-1,2,4-oxadiazole (3ad)^[8]

Colourless liquid; 29% yield (17.5 mg); mp: 60.8-62.0 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.18 (m, 2H), 8.10-8.07 (m, 1H), 7.81-7.79 (m, 1H), 7.54-7.48 (m, 4H), 7.46-7.41 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.89, 168.72, 134.81, 133.14, 132.17, 131.33, 128.91, 128.19, 127.60, 126.76, 125.81, 122.17.




3-phenyl-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3ae)^[13]

White solid; 78% yield (44.3 mg); mp: 94.4-95.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 8.39 (d, *J* = 7.7 Hz, 1H), 8.19-8.16 (m, 2H), 7.86 (d, *J* = 7.7 Hz, 1H), 7.69 (t, *J* = 7.7 Hz, 1H), 7.53-7.51 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.34, 169.18, 131.87 (q, *J* = 34.4 Hz), 131.44, 131.21, 129.84, 129.22 (q, *J* = 3.6 Hz), 128.94, 127.57, 126.58, 125.14 (q, *J* = 3.8 Hz), 123.49 (d, *J* = 272.54 Hz), 119.42; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.93




3-phenyl-5-(*p*-tolyl)-1,2,4-oxadiazole (3af)^[2]

White solid; 75% yield (35.4 mg); mp: 115.6–116.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.18–8.16 (m, 2H), 8.09 (d, *J* = 8.1 Hz, 2H), 7.51–7.49 (m, 3H), 7.33 (d, *J* = 7.7 Hz, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.86, 168.89, 143.50, 131.14, 129.83, 128.85, 128.15, 127.54, 127.10, 121.59, 21.79.




5-(4-(*tert*-butyl)phenyl)-3-phenyl-1,2,4-oxadiazole (3ag)

Colourless liquid; 67% yield (37.3 mg); ¹H NMR (400 MHz, CDCl₃) δ 8.19–8.17 (m, 2H), 8.14 (d, *J* = 8.6 Hz, 2H), 7.56 (d, *J* = 8.6 Hz, 2H), 7.51–7.50 (m, 3H), 1.37 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 175.81, 168.92, 156.50, 131.14, 128.85, 128.04, 127.56, 127.12, 126.11, 121.55, 35.22, 31.12; HRMS (m/z) [M+H]⁺ calculated for C₁₈H₁₈N₂O: 279.1492; found: 279.1494.



5-(4-fluorophenyl)-3-phenyl-1,2,4-oxadiazole (3ai)^[8]


Yellow solid; 21% yield (10.0 mg); mp: 108.3–109.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.27–8.22 (m, 2H), 8.18–8.15 (m, 2H), 7.54–7.49 (m, 3H), 7.26–7.23 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 174.81, 169.02, 165.49 (d, *J* = 256.54 Hz), 131.28, 130.63 (d, *J* = 8.7 Hz), 128.89, 127.53, 126.84, 120.70 (d, *J* = 3.3 Hz), 116.51 (d, *J* = 22.3 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -105.13.



5-(4-fluorophenyl)-3-phenyl-1,2,4-oxadiazole (3aj)^[8]


White solid; 60% yield (30.6 mg); mp: 125.6–126.4 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20–8.18 (m, 2H), 8.17–8.14 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.80,

169.05, 139.19, 131.32, 129.53, 129.46, 128.90, 127.53, 126.77, 122.77.




5-(4-bromophenyl)-3-phenyl-1,2,4-oxadiazole (3ak)^[14]

White solid; 43% yield (25.8 mg); mp: 116.8-118.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.14 (m, 2H), 8.09-8.06 (m, 2H), 7.71-7.68 (m, 2H), 7.53-7.48 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.91, 169.08, 132.51, 131.33, 129.57, 128.91, 127.75, 127.54, 126.75, 123.20.




5-(furan-2-yl)-3-phenyl-1,2,4-oxadiazole (3al)^[2]

Yellow solid; 76% yield (32.2 mg); mp: 99.1-100.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.15 (m, 2H), 7.72 (s, 1H), 7.53-7.49 (m, 3H), 7.38 (d, *J* = 3.4 Hz, 1H), 6.66-6.65 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 168.70, 167.60, 146.74, 140.16, 131.38, 128.88, 127.63, 126.49, 116.64, 112.54.



3-phenyl-5-(thiophen-2-yl)-1,2,4-oxadiazole (3am)^[2]


White solid; 56% yield (25.5 mg); mp: 106.7-107.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.14 (m, 2H), 7.96 (dd, *J* = 1.1, 3.8 Hz, 1H), 7.65 (dd, *J* = 1.1, 5.0 Hz, 1H), 7.53-7.48 (m, 3H), 7.23-7.21 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 171.37, 168.87, 131.96, 131.89, 131.27, 128.85, 128.52, 127.59, 126.71, 125.92.



3-phenyl-5-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3ao)^[8]


White solid; 64% yield (37.3mg); mp:101.0-102.0 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.33 (d, *J* = 8.2 Hz, 2H), 8.18-8.16 (m, 2H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.54-7.49 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) 174.37, 169.23, 134.25 (q, *J* = 32.8 Hz), 131.44,

128.94, 128.55 127.56, 127.44, 126.59, 126.16 (q, $J = 3.8$ Hz), 123.52 (q, $J = 271.7$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -63.19.




3-phenyl-5-(*m*-tolyl)-1,2,4-oxadiazole (3an)^[2]

White solid; 73% yield (34.5 mg); mp: 71.2-72.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.19-8.16 (m, 2H), 8.03-7.80 (m, 2H), 7.51-7.47 (m, 3H), 7.44-7.38 (m, 2H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.92, 168.93, 139.03, 133.56, 131.16, 129.02, 128.86, 128.68, 127.54, 127.05, 125.33, 124.21, 21.34.




3-(*m*-tolyl)-5-(*p*-tolyl)-1,2,4-oxadiazole (3gf)^[3]

Yellow solid solid; 72% yield (43.1 mg); mp: 123.7-124.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.10 (d, $J = 8.2$ Hz, 2H), 7.99-7.96 (m, 2H), 7.39 (t, $J = 7.5$ Hz, 1H), 7.33 (t, $J = 8.2$ Hz, 3H), 2.44 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.79, 168.99, 143.46, 138.62, 131.92, 129.81, 128.76, 128.15, 128.07, 126.94, 124.66, 121.63, 21.78, 21.39.



3-(3-chlorophenyl)-5-(*p*-tolyl)-1,2,4-oxadiazole (3hf)^[15]


White solid; 62% yield (44.4 mg); mp: 103.8-104.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (t, $J = 1.6$ Hz, 1H), 8.08 (d, $J = 8.1$ Hz, 2H), 8.06-8.03 (m, 1H), 7.50-7.47 (m, 1H), 7.43 (t, $J = 7.7$ Hz, 1H), 7.34 (d, $J = 8.1$ Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.13, 167.89, 143.73, 134.93, 131.16, 130.16, 129.87, 128.83, 128.17, 127.65, 125.57, 121.37, 21.80.



3,5-di-*p*-tolyl-1,2,4-oxadiazole (3kf)^[3]


White solid; 68% yield (43.1 mg); mp: 135.1-135.7 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.07 (q, $J = 8.1$ Hz, 4H), 7.34-7.29 (m, 4H), 2.42 (d, $J = 6.8$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.69, 168.89, 143.40, 141.42, 129.79, 129.55, 128.13, 127.45,

124.27, 121.67, 21.77, 21.61.



3-(4-methoxyphenyl)-5-(*p*-tolyl)-1,2,4-oxadiazole (3lf)^[16]

White solid; 68% yield (43.6 mg); mp: 113.4-113.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.09 (t, *J* = 8.7 Hz, 4H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.00 (d, *J* = 9.0 Hz, 2H), 3.87 (s, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.58, 168.58, 161.89, 143.37, 129.78, 129.12, 128.12, 121.70, 119.56, 114.22, 55.39, 21.77.




3-(4-fluorophenyl)-5-(*p*-tolyl)-1,2,4-oxadiazole (3nf)^[17]

White solid; 74% yield (37.5 mg); mp: 120.1-120.4 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.14 (m, 2H), 8.08 (d, *J* = 8.2 Hz, 2H), 7.34 (d, *J* = 7.9 Hz, 2H), 7.21-7.15 (m, 2H), 3.09 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.94, 168.05, 164.56 (d, *J* = 250.7 Hz), 143.60, 129.83, 129.66 (d, *J* = 8.5 Hz), 128.13, 123.33 (d, *J* = 3.1 Hz), 121.47, 116.00 (d, *J* = 22.0 Hz), 21.77; ¹⁹F NMR (376 MHz, CDCl₃) δ -108.68.



3-(4-iodophenyl)-5-(*p*-tolyl)-1,2,4-oxadiazole (3of)


White solid; 76% yield (23.1 mg); mp: 144.8-145.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.1 Hz, 2H), 7.90-7.83 (m, 4H), 7.34 (d, *J* = 8.1 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.06, 168.32, 143.69, 138.08, 129.86, 129.04, 128.16, 126.60, 121.40, 97.82, 21.80; HRMS (m/z) [M+H]⁺ calculated for C₁₅H₁₁IN₂O: 362.9989; found: 362.9988.



5-(3-(trifluoromethyl)phenyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole(3re)


White solid; 98% yield (45.7 mg); mp: 104.2-104.7 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 8.39 (d, *J* = 7.9 Hz, 1H), 8.30 (d, *J* = 8.2 Hz, 2H), 7.89 (d, *J* = 7.8 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 2H), 7.73 (t, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ

174.84, 168.20, 133.18 (q, $J = 32.5$ Hz), 132.02 (q, $J = 33.2$ Hz), 131.26, 129.96, 129.51 (q, $J = 3.6$ Hz), 128.71, 127.95, 125.95 (q, $J = 3.7$ Hz), 125.21 (q, $J = 4.0$ Hz), 124.83, 123.78 (q, $J = 271.3$ Hz), 123.45 (q, $J = 271.9$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -62.99, -63.03; HRMS (m/z) $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{16}\text{H}_8\text{F}_6\text{N}_2\text{O}$: 359.0614; found: 359.0612.




3-(*p*-tolyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rf)^[19]

White solid; 72% yield (49.2 mg); mp: 107.2-107.7 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (d, $J = 8.1$ Hz, 2H), 8.10 (d, $J = 8.4$ Hz, 2H), 7.76 (d, $J = 8.1$ Hz, 2H), 7.36 (d, $J = 8.1$ Hz, 2H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.33, 167.88, 143.85, 132.83 (q, $J = 32.0$ Hz), 130.51, 129.90, 128.19, 127.87, 125.82 (q, $J = 3.7$ Hz), 123.83 (q, $J = 272.3$ Hz), 121.29, 21.80; ^{19}F NMR (376 MHz, CDCl_3) δ -62.94.



5-(4-(tert-butyl)phenyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rg)


White solid; 69% yield (58.8 mg); mp: 103.2-103.7 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (d, $J = 7.9$ Hz, 2H), 8.14 (d, $J = 8.5$ Hz, 2H), 7.76 (d, $J = 8.2$ Hz, 2H), 7.59-7.57 (m, 2H), 1.38 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.28, 167.91, 156.85, 132.83 (q, $J = 32.3$ Hz), 130.53, 128.08, 127.90, 126.19, 125.82 (q, $J = 3.6$ Hz), 123.84 (d, $J = 273.7$ Hz), 121.23, 35.26, 31.09; ^{19}F NMR (376 MHz, CDCl_3) δ -62.93; HRMS (m/z) $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{N}_2\text{O}$: 347.1366; found: 347.1365.



5-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rh)^[7]


White solid; 78% yield (49.9 mg); mp: 142.9-143.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.27 (d, $J = 8.0$ Hz, 2H), 8.15 (d, $J = 9.0$ Hz, 2H), 7.75 (d, $J = 8.3$ Hz, 2H), 7.03 (d,

J = 8.6 Hz, 2H), 3.90 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.04, 167.79, 163.37, 132.76 (q, *J* = 32.3 Hz), 130.58, 130.13, 127.84, 125.78 (q, *J* = 3.8 Hz), 123.80 (q, *J* = 272.3 Hz), 116.53, 114.58, 55.53; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.93.




5-(4-chlorophenyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rj)^[18]

White solid; 58% yield (37.6 mg); mp: 121.5-122.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.2 Hz, 2H), 8.16-8.13 (m, 2H), 7.76 (d, *J* = 8.2 Hz, 2H), 7.55-7.52 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.26, 168.03, 139.52, 133.01 (q, *J* = 32.4 Hz), 130.15, 129.62, 129.48, 127.87, 125.88 (q, *J* = 3.7 Hz), 123.78 (q, *J* = 273.8 Hz), 122.43. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.98.



5-(4-bromophenyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rk)

White solid; 44% yield (32 mg); mp: 128.6-128.9 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 7.9 Hz, 2H), 8.09-8.06 (m, 2H), 7.77 (d, *J* = 8.2 Hz, 2H), 7.72-7.69 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 175.38, 168.06, 133.03 (q, *J* = 32.4 Hz), 132.60, 130.13, 129.58, 128.08, 127.88, 125.89 (q, *J* = 3.7 Hz), 123.77 (d, *J* = 271.9 Hz), 122.86. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.98; HRMS (m/z) [M+H]⁺ calculated for C₁₅H₈BrF₃N₂O: 368.9845; found: 368.9845.





5-(furan-2-yl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (3rl)


White solid; 77% yield (36.4 mg); mp: 104.9-105.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 8.2 Hz, 2H), 7.78-7.74 (m, 3H), 7.40 (d, *J* = 3.5 Hz, 1H), 6.67 (q, *J* = 1.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 167.98, 167.70, 147.00, 139.89, 133.06 (q, *J* = 32.4 Hz), 129.91, 127.97, 125.87 (q, *J* = 3.7 Hz), 125.12 (q, *J* = 272.4 Hz), 117.05, 112.64; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.01; HRMS (m/z) [M+H]⁺



calculated for C₁₃H₇F₃N₂O₂: 281.0532; found: 281.0533.



5. Copies of ^1H , ^{13}C , ^{19}F NMR Spectra for the Products


















T: FTMS + p ESI Full lock ms [80.0000-1200.0000]









T: FTMS + p ESI Full lock ms [80.0000-1200.0000]






















































—175.940
—168.274


132.901
132.160
139.161
139.045
128.198
125.938
125.765
124.140









































































































































T: FTMS + p ESI Full lock ms [80.0000-1200.0000]
















T: FTMS + p ESI Full lock ms [80.0000-1200.0000]





I: ESI MS + p ESI Full lock ms [80.0000-1200.0000]



6. References

- [1] J. C. P. Mayer, T. V. Acunha, O. E. D. Rodrigues, D. F. Back, O. A. Chaves, L. Dornelles, B. A. Iglesias, *New J. Chem.*, 2021, **45**, 471-484.
- [2] W. Wang, H. Xu, Y. Q. Xu, T. Ding, W. K. Zhang, Y. R. Ren and H. B. Chang, *Org. Biomol. Chem.*, 2016, **14**, 9814-9822.
- [3] H. A. Swarup, N. Chaithra, K. Mantelingu, K. S. Rangappa, *ChemistrySelect*, 2018, **3**, 5390-5394.
- [4] S. Kandrea, P. R. Bhagatb, R. Sharmaa, A. Gupte, *Tetrahedron Lett.*, 2013, **54**, 3526-3529.
- [5] C. Wang, X. Y. Rui, D. J. Si, R. P. Dai, Y. Y. Zhu, H. M. Wen, W. Li and J. Liu, *Adv. Synth. Catal.*, 2021, **363**, 1-10.
- [6] Y. Zhang, C. J. Wu, X. Y. Wan, C. D. Wan, *J. Heterocycl. Chem.*, 2021, **58**, 1-11.
- [7] A. Savateev, N. V. Tarakina, V. Strauss, T. Hussain, K. T. Brummelhuis, J. M. S. Vadillo, Y. Markushyna, S. Mazzanti, A. P. Tyutyunnik, R. Walczak, M. Oschatz, D. Guldi, A. Karton and M. Antonietti, *Angew. Chem. Int. Ed.*, 2020, **59**, 15061-15068.
- [8] C. Jiang, M. F. Li, L. T. Xu, Y. J. Yi, J. Ye and A. X. Hu, *Org. Biomol. Chem.*, 2021, **19**, 10611-10616.
- [9] M. R. Kuram, W. G. Kim, K. Myung, and S. Y. Hong, *Eur. J. Org. Chem.*, 2016, **2016**, 438-442.
- [10] A. A. Shetneva, V. E. Pankratievab, A. S. Kunichkinab, A. S. Vlasova, I. K. Proskurinab, A. D. Kotovb and M. K. Korsakova, *Russ. J. Org. Chem.*, 2020, **56**, 1181-1186.
- [11] P. D. Parker, J. G. Pierce, *Synthesis*, 2016, **48**, 1902-1909.
- [12] T. Ramu, S. Prasanthi, N. Mangarao, G. M. Basha,R. Srinivasarao, and V. Siddaiah, *Chem. Lett.*, 2013, **42**, 722-724.
- [13] E. Li, M. Wang, Z. Wang, W. Q. Yu and J. B. Chang, *Tetrahedron*, 2018, **74**, 4613-4618.
- [14] M. Zarei, *ChemistrySelect*, 2018, **3**, 11273-11276.
- [15] M. Adib, A. H. Jahromi, N. Tavoosi, M. Mahdavia and H. R. Bijanzadeh, *Tetrahedron Lett.*, 2006, **47**, 2965-2967.
- [16] S. Li, P. H. *Adv. Synth. Catal.*, 2017, **359**, 772-778.
- [17] M. Nakka, R. Tadikonda, S. Nakka and S. Vidavalur, *Adv. Synth. Catal.*, 2016, **358**: 520-525.
- [18] R. F. Poulain, A. L. Tartara and B. P. De prez, *Tetrahedron Lett.*, 2001, **42**, 1495-1498.
- [19] M. D. Evans, J. Ring, A. Schoen, A. Bell, P. Edwards, D. Berthelot, R. Nicawonger and C. M. Baldino, *Tetrahedron Lett.*, 2003, **44**: 9337-9341.